Evidence map›Paper›PMID 14526170›Full record

ArticleCytogenetic and genome research2003

WWOX, the common chromosomal fragile site, FRA16D, cancer gene.

J H Ludes-Meyers, A K Bednarek, N C Popescu, M Bedford, C M Aldaz

Open access · greenAbstract read
In one paragraph

Article in Cytogenetic and genome research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Cellular Expression and Subcellular Localization of Wwox Protein During Testicular Development and Spermatogenesis in Rats.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021
    Article
  5. Article
  6. Article
  7. Small RNAs, Big Diseases.International journal of molecular sciences · 2020
    Review
  8. Article
  9. Article
  10. Immunohistochemical WWOX Expression and Association with Angiogenesis, p53 Expression, Cell Proliferation and Clinicopathological Parameters in Cervical Cancer.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2018
    Article
  11. Article
  12. Frontiers in oncology · 2018
    Review
  13. Article
  14. Article
  15. WWOX: a fragile tumor suppressor.Experimental biology and medicine (Maywood, N.J.) · 2015
    Review
  16. WWOX, large common fragile site genes, and cancer.Experimental biology and medicine (Maywood, N.J.) · 2015
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

J H Ludes-MeyersDepartment of Carcinogenesis, The University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, TX 78957, USA.
A K Bednarek
N C Popescu
M Bedford
C M Aldaz
The University of Texas MD Anderson Cancer Center · USGenesis Foundation · USMedical University of Lodz · PLNational Institutes of Health · US

Funding

Characterization of WWOX, the Cancer Gene Spanning FREA16DR01CA102444 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ALDAZ, C. MARCELO · 2003 to 2014
$3.3M
NCI NIH HHS R01 CA102444
6 · The paper itself

Abstract

Gross chromosomal rearrangements and aneuploidy are among the most common somatic genomic abnormalities that occur during cancer initiation and progression, in particular in human solid tumor carcinogenesis. The loss of large chromosomal regions as consequence of gross rearrangements (e.g. deletions, monosomies, unbalanced translocations and mitotic recombination) have been traditionally associated with the existence of tumor suppressor genes within the areas affected by the loss of genetic material. The long arm of chromosome 16 was identified as being frequently associated with structural abnormalities in multiple neoplasias, that led us to focus attention on the detailed genetic dissection of this region resulting in the cloning of the putative tumor suppressor gene, WWOX (WW domain containing Oxidoreductase). Interestingly, the WWOX gene resides in the very same region as that of the common chromosomal fragile site 16D (FRA16D). The WWOX gene encodes a protein that contains two WW domains, involved in protein-protein interactions, and a short chain dehydrogenase (SDR) domain, possibly involved in sex-steroid metabolism. We have identified the WWOX WW domain ligand as the PPXY motif confirming the biochemical activity of this domain. WWOX normally resides in the Golgi and we will demonstrate that Golgi localization requires an intact SDR. Inactivation of the WWOX gene during tumorigenesis can occur by homozygous deletions and possibly mutation, however, aberrantly spliced forms of WWOX mRNA have been observed even when one allele is still intact. The aberrantly spliced mRNAs have deletions of the exons that encode the SDR and these WWOX protein isoforms display abnormal intracellular localization to the nucleus possibly functioning as dominant negative inhibitors of full length WWOX. Thus, generation of aberrant transcripts of WWOX may represent a novel mechanism to functionally inactivate WWOX without genomic alteration of the remaining allele. In this article we will review the cloning and identification of WWOX as the target of FRA16D. In addition, we will discuss the possible biochemical functions of WWOX and present evidence that ectopic WWOX expression inhibits tumor growth.

Indexed as

Alternative SplicingAmino Acid SequenceBlotting, WesternBreast NeoplasmsCarrier ProteinsCell Line, TumorChromosome Fragile SitesChromosome MappingChromosomes, Human, Pair 16Cloning, MolecularGene Expression Regulation, NeoplasticGenes, Tumor SuppressorGolgi ApparatusHumansIn Situ Hybridization, FluorescenceLoss of HeterozygosityCarrier ProteinsNeoplasm ProteinsRNA, Messenger

Identifiers

PMID14526170
PMCPMC4150470
OpenAlexW2037032898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.